Published in J Pharmacol Exp Ther on November 01, 1988
Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc Natl Acad Sci U S A (1992) 3.02
A genetic determinant of the striatal dopamine response to alcohol in men. Mol Psychiatry (2010) 2.02
Inverse agonism at G protein-coupled receptors: (patho)physiological relevance and implications for drug discovery. Br J Pharmacol (2000) 1.25
Buprenorphine and opioid antagonism, tolerance, and naltrexone-precipitated withdrawal. J Pharmacol Exp Ther (2010) 0.84
Inability of an opioid antagonist lacking negative intrinsic activity to induce opioid receptor up-regulation in vivo. Br J Pharmacol (1991) 0.80
Buprenorphine differentially alters opioid receptor adaptation in rat brain regions. J Pharmacol Exp Ther (1996) 0.79
Chaperone-like effects of cell-permeant ligands on opioid receptors. Front Biosci (Landmark Ed) (2009) 0.79
Quantitative autoradiography of adenosine receptors in brains of chronic naltrexone-treated mice. Br J Pharmacol (2003) 0.75
Psychotomimesis mediated by kappa opiate receptors. Science (1986) 3.60
Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc Natl Acad Sci U S A (1992) 3.02
Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins. Proc Natl Acad Sci U S A (1989) 2.51
Analgesic effect of intraarticular morphine after arthroscopic knee surgery. N Engl J Med (1991) 2.29
Motivational properties of kappa and mu opioid receptor agonists studied with place and taste preference conditioning. Psychopharmacology (Berl) (1985) 2.16
Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats. J Pharmacol Exp Ther (1993) 2.01
Peripheral opioid receptors mediating antinociception in inflammation. Evidence for involvement of mu, delta and kappa receptors. J Pharmacol Exp Ther (1989) 1.89
Opioids from immunocytes interact with receptors on sensory nerves to inhibit nociception in inflammation. Proc Natl Acad Sci U S A (1990) 1.79
The effects of opioid peptides on dopamine release in the nucleus accumbens: an in vivo microdialysis study. J Neurochem (1990) 1.71
Unilateral inflammation of the hindpaw in rats as a model of prolonged noxious stimulation: alterations in behavior and nociceptive thresholds. Pharmacol Biochem Behav (1988) 1.60
On the central sites for the antinociceptive action of morphine and fentanyl. Neuropharmacology (1970) 1.57
Development of physical dependence on morphine in respect to time and dosage and quantification of the precipitated withdrawal syndrome in rats. Psychopharmacologia (1973) 1.46
Intrinsic mechanisms of antinociception in inflammation: local opioid receptors and beta-endorphin. J Neurosci (1990) 1.41
Physical interaction between the serotonin transporter and neuronal nitric oxide synthase underlies reciprocal modulation of their activity. Proc Natl Acad Sci U S A (2007) 1.38
Microelectrophoretic studies concerning the spread of glutamic acid and GABA in brain tissue. Exp Brain Res (1969) 1.32
Inflammation of the rat paw enhances axonal transport of opioid receptors in the sciatic nerve and increases their density in the inflamed tissue. Neuroscience (1993) 1.29
Evidence that the aversive effects of opioid antagonists and kappa-agonists are centrally mediated. Psychopharmacology (Berl) (1989) 1.23
Aspects of opiate dependence in the myenteric plexus of the guinea-pig. Life Sci (1976) 1.23
Differential effects of mu and kappa opioid systems on motivational processes. NIDA Res Monogr (1986) 1.23
In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonistic and antagonistic actions. Br J Pharmacol (1981) 1.21
(1-(2,5-dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT) 2A receptors: modulation by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists. J Pharmacol Exp Ther (1995) 1.21
Preference conditioning produced by opioid active and inactive isomers of levorphanol and morphine in rat. Life Sci (1986) 1.20
Examination of the neurochemical substrates mediating the motivational effects of opioids: role of the mesolimbic dopamine system and D-1 vs. D-2 dopamine receptors. J Pharmacol Exp Ther (1993) 1.18
Binding characteristics of a monoclonal beta-endorphin antibody recognizing the N-terminus of opioid peptides. J Neurochem (1983) 1.17
Place preference conditioning reveals the involvement of D1-dopamine receptors in the motivational properties of mu- and kappa-opioid agonists. Brain Res (1987) 1.16
Electrically stimulated release of opiate-like material from the myenteric plexus of the guinea pig ileum. Eur J Pharmacol (1977) 1.16
Monoclonal antibody to the message sequence Tyr-Gly-Gly-Phe of opioid peptides exhibits the specificity requirements of mammalian opioid receptors. Proc Natl Acad Sci U S A (1983) 1.14
Opiate receptor binding sites in human brain. Brain Res (1982) 1.12
Spontaneous association between opioid receptors and GTP-binding regulatory proteins in native membranes: specific regulation by antagonists and sodium ions. Mol Pharmacol (1990) 1.10
Electrophoretic release of tritium-labelled glutamic acid from micropipettes in vitro. Brain Res (1969) 1.10
Selective receptors for beta-endorphin on the rat vas deferens. Life Sci (1979) 1.09
Multiple opioid systems and pain. Pain (1986) 1.08
Gene expression and localization of opioid peptides in immune cells of inflamed tissue: functional role in antinociception. Neuroscience (1992) 1.07
Calcium reverses the inhibitory action of morphine on neuroeffector transmission in the mouse vas deferens. Brain Res (1980) 1.07
Pharmacologically induced alterations of cortical and subcortical evoked potentials compared with physiological changes during the awake-sleep cycle in cats. Electroencephalogr Clin Neurophysiol (1967) 1.06
Peripheral mechanisms of opioid antinociception in inflammation: involvement of cytokines. Eur J Pharmacol (1993) 1.05
Molecular requirements involved in suppression of EAE by synthetic basic copolymers of amino acids. Immunochemistry (1976) 1.05
Serotonin (5-HT)2A receptor activation enhances dialysate levels of dopamine and noradrenaline, but not 5-HT, in the frontal cortex of freely-moving rats. Neuropharmacology (1999) 1.05
Buprenorphine: differential interaction with opiate receptor subtypes in vivo. J Pharmacol Exp Ther (1982) 1.04
Possible antidepressive effects of opioids: action of buprenorphine. Ann N Y Acad Sci (1982) 1.04
Studies on the central antinociceptive action of cholinomimetic agents. Int J Neuropharmacol (1969) 1.04
Actions of alpha2 adrenoceptor ligands at alpha2A and 5-HT1A receptors: the antagonist, atipamezole, and the agonist, dexmedetomidine, are highly selective for alpha2A adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol (1998) 1.03
Antinociceptive effects of mu- and kappa-agonists in inflammation are enhanced by a peripheral opioid receptor-specific mechanism. Eur J Pharmacol (1988) 1.01
Piribedil enhances frontocortical and hippocampal release of acetylcholine in freely moving rats by blockade of alpha 2A-adrenoceptors: a dialysis comparison to talipexole and quinelorane in the absence of acetylcholinesterase inhibitors. J Pharmacol Exp Ther (2003) 1.01
Kappa-opioid receptor-mediated antinociception in the rat. II. Supraspinal in addition to spinal sites of action. J Pharmacol Exp Ther (1989) 1.01
Characteristics of a monoclonal beta-endorphin antibody recognizing the N-terminus of opioid peptides. Life Sci (1983) 1.01
Mixed opioid/nonopioid effects of dynorphin and dynorphin related peptides after their intrathecal injection in rats. Neuropeptides (1983) 0.99
Pharmacokinetics of fentanyl in man and the rabbit. Eur J Clin Pharmacol (1972) 0.99
Highly specific opiate receptors for dynorphin-(1-13) in the mouse vas deferens. Eur J Pharmacol (1980) 0.99
Dynorphin-related immunoreactive peptides in rat brain and pituitary. Neurosci Lett (1980) 0.99
Involvement of capsaicin-sensitive neurones in hyperalgesia and enhanced opioid antinociception in inflammation. Naunyn Schmiedebergs Arch Pharmacol (1990) 0.98
Stimulation of hypothalamic beta-endorphin and dynorphin release by corticotropin-releasing factor (in vitro). Brain Res (1986) 0.98
Enkephalin-induced inhibition of cortical neurones and the lack of this effect in morphine tolerant/dependent rats. Brain Res (1976) 0.98
Neuroanatomical substrates mediating the aversive effects of D-1 dopamine receptor antagonists. Psychopharmacology (Berl) (1991) 0.97
Specificity of opioids towards the mu-, delta- and epsilon-opiate receptors. Neurosci Lett (1979) 0.97
A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194. J Pharmacol Exp Ther (1998) 0.97
Demonstration and characterization of alpha-human atrial natriuretic factor in human plasma. FEBS Lett (1985) 0.97
GTPase and adenylate cyclase desensitize at different rates in NG108-15 cells. Mol Pharmacol (1987) 0.96
Motivational properties of opioids: evidence that an activation of delta-receptors mediates reinforcement processes. Brain Res (1987) 0.96
Changes in EEG spectral power in the prefrontal cortex of conscious rats elicited by drugs interacting with dopaminergic and noradrenergic transmission. Br J Pharmacol (1999) 0.96
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study. Eur J Pharmacol (1998) 0.96
Sites of action of morphine involved in the development of physical dependence in rats. II. Morphine withdrawal precipitated by application of morphine antagonists into restricted parts of the ventricular system and by microinjection into various brain areas. Psychopharmacologia (1976) 0.95
Buprenorphrine: demonstration of physical dependence liability. Eur J Pharmacol (1981) 0.95
Peripheral effect of fentanyl upon nociception in inflamed tissue of the rat. Neurosci Lett (1988) 0.95
Motivational effects of opioids: influence of D-1 versus D-2 receptor antagonists. Eur J Pharmacol (1988) 0.95
Beta-endorphin and dynorphin control serum luteinizing hormone level in immature female rats. Nature (1981) 0.95
Endorphinergic modulation of neural reward systems indicated by behavioral changes. Pharmacol Biochem Behav (1984) 0.94
Potentiation of the fluoxetine-induced increase in dialysate levels of serotonin (5-HT) in the frontal cortex of freely moving rats by combined blockade of 5-HT1A and 5-HT1B receptors with WAY 100,635 and GR 127,935. J Neurochem (1997) 0.94
Discriminative stimulus properties of the novel serotonin (5-HT)2C receptor agonist, RO 60-0175: a pharmacological analysis. Neuropharmacology (1999) 0.94
The influence of chronic stress on multiple opioid peptide systems in the rat: pronounced effects upon dynorphin in spinal cord. Brain Res (1987) 0.94
Intracellular studies on the action of L-glutamic acid on spinal neurones of the cat. Brain Res (1972) 0.94
Inflammation of the hind limb as a model of unilateral, localized pain: influence on multiple opioid systems in the spinal cord of the rat. Pain (1988) 0.94
Noradrenaline and adrenaline are high affinity agonists at dopamine D4 receptors. Eur J Pharmacol (1997) 0.94
G protein activation by human dopamine D3 receptors in high-expressing Chinese hamster ovary cells: A guanosine-5'-O-(3-[35S]thio)- triphosphate binding and antibody study. Mol Pharmacol (1999) 0.93
[Statistical properties of neuron activity in the ascending visual system]. Kybernetik (1964) 0.93
Antinociceptive profiles of non-peptidergic neurokinin1 and neurokinin2 receptor antagonists: a comparison to other classes of antinociceptive agent. Pain (1995) 0.93
Human dopamine D(3) receptors mediate mitogen-activated protein kinase activation via a phosphatidylinositol 3-kinase and an atypical protein kinase C-dependent mechanism. Mol Pharmacol (1999) 0.92
Opiate activity and receptor selectivity of dynorphin1-13 and related peptides. Neurosci Lett (1980) 0.92
Analgesic effects of mu-, delta- and kappa-opiate agonists and, in particular, dynorphin at the spinal level. Life Sci (1983) 0.92
Comparison of in vivo and in vitro parameters of opiate receptor binding in naive and tolerant dependent rodents. Life Sci (1975) 0.91
Identification of the opioid receptor types mediating beta-endorphin-induced alterations in dopamine release in the nucleus accumbens. Eur J Pharmacol (1990) 0.91
Opioid receptors are coupled tightly to G proteins but loosely to adenylate cyclase in NG108-15 cell membranes. Mol Pharmacol (1988) 0.91
Centrally and peripherally mediated inhibition of intestinal motility by opioids. Naunyn Schmiedebergs Arch Pharmacol (1979) 0.91
Multiple opiate receptors in peripheral tissue preparations. Biochem Pharmacol (1981) 0.90
Blockade of the discriminative stimulus effects of DOI by MDL 100,907 and the 'atypical' antipsychotics, clozapine and risperidone. Eur J Pharmacol (1994) 0.90
Radioimmunoassay of beta-endorphin basal and stimulated levels in extracted rat plasma. Naunyn Schmiedebergs Arch Pharmacol (1978) 0.90
Citalopram reduces social interaction in rats by activation of serotonin (5-HT)(2C) receptors. Neuropharmacology (2000) 0.90
Non-opioid psychotomimetic-like discriminative stimulus properties of N-allylnormetazocine (SKF 10,047) in the rat. Eur J Pharmacol (1982) 0.90
Peptide neuroanatomy of adjuvant-induced arthritic inflammation in rat. Agents Actions (1988) 0.89
Monoclonal anti-idiotypic antibodies to opioid receptors. J Biol Chem (1988) 0.89
Lack of cross-tolerance on multiple opiate receptors in the mouse vas deferens. Mol Pharmacol (1980) 0.89
Aversive properties of naloxone in non-dependent (naive) rats may involve blockade of central beta-endorphin. Psychopharmacology (Berl) (1985) 0.89
Opioid dependence in the guinea-pig myenteric plexus is controlled by non-tolerant and tolerant opioid receptors. Eur J Pharmacol (1985) 0.89